Century Therapeutics Stock (NASDAQ:IPSC)
Previous Close
$2.26
52W Range
$0.43 - $3.04
50D Avg
$2.29
200D Avg
$1.19
Market Cap
$192.18M
Avg Vol (3M)
$1.32M
Beta
1.67
Div Yield
-
IPSC Company Profile
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| OSTX | OS Therapies Incorporated |
| COEP | Coeptis Therapeutics, Inc. |
| CUE | Cue Biopharma, Inc. |
| OTLK | Outlook Therapeutics, Inc. |
| MDCX | Medicus Pharma Ltd. Common Stock |
| SNTI | Senti Biosciences, Inc. |
| EQ | Equillium, Inc. |
| TELO | Telomir Pharmaceuticals, Inc. Common Stock |
| GNTA | Genenta Science S.p.A. |
| KPTI | Karyopharm Therapeutics Inc. |